Financials
- Fiscal year
- 2025
- Total assets
- €743,843
- Loss
- -€37,513
- Solvency
- -44.7%
CASEPRO
ActiveSummary
The computed 12-month bankruptcy probability of CASEPRO is 3.3% (moderate). The 2025 annual accounts show negative equity (-€332,451) and a net result of -€37,513. Equity is shrinking by ~14.8% per year across the filed fiscal years. Its solvency ranks better than 12% of 12918 sector peers (fiscal year 2025). The company has been active since 2017 and the Belgian State Gazette contains no insolvency or warning signals.
Overview
Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
1 site
Size
€743,843total assets 2025
- Equity
- -€332,451
- Loss
- -€37,513
Turnover not published (abridged schema)
Structure
Accounts 32 d early0 of 3 deeds read
Why 48- Liquidity: current ratio 0.69- 2 of the last 3 late- Negative equity -€332,451+ Size: total assets €743,843Show the evidence
Checked score
Score 2025
48
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Better than 12% of its sector peers (NACE 46, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2024
Weak
Solvency
0=
equity -44.7% of total assets
Liquidity
0=
short-term debt 144.7%
Profitability
12-1
return on assets -5.0%
Bankruptcy probability, 12 months
3.3%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 6.3%
12-2024: 7.6%▲ +20.1% vs 11-2024
01-2025: 10.1%▲ +33.5% vs 12-2024
02-2025: 10.1%● 0.0% vs 01-2025
03-2025: 10.3%▲ +1.8% vs 02-2025
04-2025: 9.4%▼ -8.5% vs 03-2025
05-2025: 9.4%▼ -0.5% vs 04-2025
06-2025: 8.9%▼ -4.9% vs 05-2025
07-2025: 8.9%● 0.0% vs 06-2025
08-2025: 10.9%▲ +21.8% vs 07-2025highest value
09-2025: 10.9%● 0.0% vs 08-2025highest value
10-2025: 3.8%▼ -64.7% vs 09-2025
11-2025: 3.8%● 0.0% vs 10-2025
12-2025: 3.8%● 0.0% vs 11-2025
01-2026: 3.8%● 0.0% vs 12-2025
02-2026: 3.8%● 0.0% vs 01-2026
03-2026: 3.8%▼ -1.9% vs 02-2026
04-2026: 3.7%▼ -1.9% vs 03-2026
05-2026: 3.7%▼ -0.6% vs 04-2026
06-2026: 3.5%▼ -3.9% vs 05-2026
07-2026: 3.4%▼ -2.5% vs 06-2026
08-2026: 3.4%● 0.0% vs 07-2026
09-2026: 3.3%▼ -3.1% vs 08-2026lowest value
10-2026: 3.3%● 0.0% vs 09-2026lowest value
- Liquidity: current ratio 0.69 raises the probability
- 2 of the last 3 late raises the probability
- Size: total assets €743,843 lowers the probability for this profile
- Negative equity -€332,451 raises the probability
No credit on open account
Liquidity short (current ratio 0.69 against 0.69 in 2024; short-term debt: 144.7% of total assets), and equity is negative.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 46, micro). Better than this share of them on solvency 6%, liquidity 1%, profitability 18%, growth against the median 23%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
181920222425
2018 to 2025 · latest year -€332,451
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
32 d early
2024
47 d late
2022
59 d late
2020
788 d late
2019
411 d late
2018
115 d late
2017
29 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 202 days after the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 28 September (4 of the last 5 filed years within 353 days of that day).
Companies Code · seven monthsPosition in the running window
03-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · micro…
- Annual accounts filedfiscal year 2024 · micro…
- Annual accounts filedfiscal year 2022 · micro…
Key points
By topic
Timeline
- Events
- 7
- Since
- 2018
- Next accounts
- by 31-07-2027
- 29-06-2026Annual accounts filed
- 16-09-2025Annual accounts filed
- 28-09-2023Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Founded
- 04-04-2017
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.